Valdosta Daily Times

National, International News

March 25, 2013

Court: Can drug companies pay to delay generics?

WASHINGTON — Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines that can top 90 percent.

The Obama administration, backed by consumer groups and the American Medical Association, says these so-called “pay for delay” deals profit the drug companies but harm consumers by adding 3.5 billion annually to their drug bills.

But the pharmaceutical companies counter that they need to preserve longer the billions of dollars in revenue from their patented products in order to recover the billions they spend developing new drugs. And both the large companies and the generic makers say the marketing of generics often is hastened by these deals.

The justices will hear the argument Monday.

Such pay-for-delay deals arise when generic companies file a challenge at the Food and Drug Administration to the patents that give brand-name drugs a 20-year monopoly. The generic drugmakers aim to prove the patent is flawed or otherwise invalid, so they can launch a generic version well before the patent ends.

Brand-name drugmakers then usually sue the generic companies, which sets up what could be years of expensive litigation. When the two sides aren’t certain who will win, they often reach a compromise deal that allows the generic company to sell its cheaper copycat drug in a few years — but years before the drug’s patent would expire. Often, that settlement comes with a sizeable payment from the brand-name company to the generic drugmaker.

Numerous brand-name and generic drugmakers and their respective trade groups say the settlements protect their interests but also benefit consumers by bringing inexpensive copycat medicines to market years earlier than they would arrive in any case generic drugmakers took to trial and lost. But federal officials counter that such deals add billions to the drug bills of American patients and taxpayers, compared to what would happen if the generic companies won the lawsuits and could begin marketing right away.

A study by RBC Capital Markets Corp. of 371 cases during 2000-2009 found brand-name companies won 89 at trial compared to 82 won by generic drugmakers. Another 175 ended in settlement deals, and 25 were dropped.

Generic drugs account for about 80 percent of all American prescriptions for medicines and vaccines, but a far smaller percentage of the $325 billion spent by U.S. consumers on drugs each year. Generics saved American patients, taxpayers and the healthcare system an estimated $193 billion in 2011 alone, according to health data firm IMS Health.

But government officials believe the number of potentially anticompetitive patent settlements is increasing. Pay-for-delay deals increased from 28 to 40 in just the last two fiscal years and the deals in fiscal 2012 covered 31 brand-name pharmaceuticals, Federal Trade Commission officials said. Those had combined annual U.S. sales of more than $8.3 billion.

The Obama administration argues the agreements are illegal if they’re based solely on keeping the generic drug off the market. Solicitor General Donald Verrilli, speaking at Georgetown Law School recently, noted that once a generic drug gets on the market and competes with a brand-name drug, “the price drops 85 percent.” That quickly decimates sales of the brand-name medicine.

“These agreements should actually be considered presumptively unlawful because of the potential effects on consumers,” Verrilli said.

In the case before the court, Brussels, Belgium-based Solvay — now part of a new company called AbbVie Inc. — reached a deal with generic drugmaker Watson Pharmaceuticals allowing it to launch a cheaper version of Solvay’s male hormone drug AndroGel in August 2015.  Solvay agreed to pay Watson an estimated $19 million-$30 million annually, government officials said. The patent runs until August 2020. Watson agreed to also help sell the brand-name version, AndroGel.

AndroGel, which brought in $1.2 billion last year for AbbVie, is a gel applied to the skin daily to treat low testosterone in men. Low testosterone can affect sex drive, energy level, mood, muscle mass and bone strength.

The FTC called the deal anticompetitive and sued Watson, now called Actavis Inc.

The 11th U.S. Circuit Court of Appeals in Atlanta rejected the government’s objections, and the FTC appealed to the Supreme Court.  

The federal district and appellate courts both ruled against the government, AbbVie, which is based in North Chicago, Ill., said.  “We are confident that these decisions will be upheld by the Supreme Court.”

The Generic Pharmaceutical Association’s head, Ralph Neas, said the settlements are “pro-consumer, pro-competition and transparent.” He said every patent settlement to date has brought a generic drug to market before the relevant patent ended, with two-thirds of the new generic drugs launched in 2010 and 2011 hitting the market early due to a settlement.

“By doing what the FTC wants, you’re going to hurt consumers rather than help them,” said Paul Bisaro, CEO of Actavis of Parsippany, N.J.

Bisaro said consumers will save an estimated $50 billion just from patent settlements involving Lipitor, the cholesterol-lowering drug made by Pfizer Inc. of New York that reigned for nearly a decade as the world’s top-selling drug.

Lipitor’s patent ran until 2017, but multiple generic companies challenged it. Pfizer reached a settlement that enabled Actavis and a second company to sell slightly cheaper generic versions starting Nov. 30, 2011 and several other generic drugmakers to begin selling generic Lipitor six months later. The price then plummeted from Pfizer’s $375 to $530 for a three-month supply, depending on dosage, to $20 to $40 for generic versions.

Because generic companies tend to challenge patents of every successful drug, the FTC’s position would impose onerous legal costs on brand-name drugmakers and limit their ability to fund expensive research to create new drugs, said the Pharmaceutical Research and Manufacturers of America, which represents brand-name drugmakers.

According to the 2010 RBC Capital Markets study, when trial victories, settlements between drugmakers and dropped cases are combined, generic companies were able to bring their product to market before the brand-name drug’s patent expired in 76 percent of the 371 drug patent suits decided from 2000 through 2009.

Consumer, doctor and drugstore groups have lined up to support the Obama administration in this case.

“AARP believes it is in the interest of those fifty and older, and indeed the public at large, to hasten the entry of generic prescription drugs to the marketplace,” said Ken Zeller, senior attorney with the AARP Foundation Litigation. “Pay-for-delay agreements such as those at issue in this case frustrate that public interest.”

The American Medical Association, the giant doctors’ group, believes pay-for-delay agreements undermine the balance between spurring innovation through patents and fostering competition through generics, AMA President Dr. Jeremy A., Lazarus said. “Pay for delay must stop to ensure the most cost-effective treatment options are available to patients.”

Drugstores also believe pay-for-delay deals “pose considerable harm to patients because they postpone the availability of generic drugs which limits patient access to generic medications,” said Chrissy Kopple of the National Association of Chain Drug Stores.

Eight justices will decide this case later this year. Justice Samuel Alito did not take part in considering whether to take this case and is not expected to take part in arguments.

1
Text Only
National, International News
  • Stowaway teen forces review of airport security

    A 15-year-old boy found his way onto an airport’s tarmac and climbed into a jetliner’s wheel well, then flew for five freezing hours to Hawaii — a misadventure that forced authorities to take a hard look at the security system that protects the nation’s airline fleet.

    April 22, 2014

  • South Korea Ship Sink_Rich copy.jpg Death count in ferry sinking tops 100

    One by one, coast guard officers carried the newly arrived bodies covered in white sheets from a boat to a tent on the dock of this island, the first step in identifying a sharply rising number of corpses from a South Korean ferry that sank nearly a week ago.

    April 22, 2014 1 Photo

  • AP520422034 copy.jpg Today in History for Tuesday, April 22, 2014

    Today is Tuesday, April 22, the 112th day of 2014. There are 253 days left in the year.

    April 22, 2014 1 Photo

  • Immigration _Rich copy.jpg DHS secretary re-evaluating deportation priorities

    Homeland Security Secretary Jeh Johnson said Wednesday he’s re-evaluating the Obama administration’s deportation priorities to make certain they’re focused on national security, public safety and border security, amid growing pressure from the Latino community and President Barack Obama’s fellow Democrats. 

    April 22, 2014 1 Photo

  • Rethinking Pot 420_Rich copy.jpg Public smoke-out marks pot holiday in Colorado

    Tens of thousands of revelers raised joints, pipes and vaporizer devices to the sky Sunday at a central Denver park in a defiant toast to the April 20 pot holiday, a once-underground celebration that stepped into the mainstream in the first state in the nation to legalize recreational marijuana.

    April 21, 2014 1 Photo

  • Submarine Sleep Sched_Rich copy.jpg Navy OKs changes for submariners’ sleep schedules

    With no sunlight to set day apart from night on a submarine, the U.S. Navy for decades has staggered sailors’ working hours on schedules with little resemblance to life above the ocean’s surface.

    April 21, 2014 1 Photo

  • South Korea Ship Sink_Rich copy.jpg Grim work for families as more bodies discovered

    There are no names listed as relatives huddle around signboards to identify bodies from a sunken ferry. Just the slimmest of clues about mostly young lives now lost. Many favored hoodies and track pants. One girl painted her fingernails red and toenails black. Another had braces on her teeth.

    April 21, 2014 1 Photo

  • AP600421099 copy.jpg Today in History for Monday, April 21, 2014

    Today is Monday, April 21, the 111th day of 2014. There are 254 days left in the year.

    April 21, 2014 1 Photo

  • Space Robot_Rich copy.jpg NASA’s Robonaut finally getting legs

    Robonaut, the first out-of-this-world humanoid, is finally getting its space legs.

    April 20, 2014 1 Photo

  • Nepal Everest Avalanc_Rich copy.jpg Another body pulled from snow in avalanche

    Search teams recovered a 13th body Saturday from the snow and ice covering a dangerous climbing pass on Mount Everest, where an avalanche a day earlier swept over a group of Sherpa guides in the deadliest disaster on the world’s highest peak.

    April 20, 2014 1 Photo

Top News
Poll

Given the amount of rain recently, what's your favorite “rain” song?

Singing in the Rain
Purple Rain
Have You Ever Seen the Rain?
November Rain
Rainy Night in Georgia
Other
     View Results